| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/23/2006 | WO2006020999A2 Pterostilbene as a new agonist for the peroxisome proliferator-activated receptor alpha isoform |
| 02/23/2006 | WO2006020994A2 Compositions and methods using hyaluronic acid and hyluronidase inhibitors |
| 02/23/2006 | WO2006020984A2 Cyclosporin formulations |
| 02/23/2006 | WO2006020980A1 Agglomeration of sterol particles having a particular size |
| 02/23/2006 | WO2006020916A2 Modulators of ppar and methods of their preparation |
| 02/23/2006 | WO2006020912A2 Treatments for congestive heart failure |
| 02/23/2006 | WO2006020891A2 Chemokine combinations to mobilize progenitor/stem cells |
| 02/23/2006 | WO2006020853A2 Pharmaceutical composition and method for treating neurodegenerative disorders |
| 02/23/2006 | WO2006020852A2 Pharmaceutical composition and method for treating neurodegenerative disorders |
| 02/23/2006 | WO2006020850A2 Pharmaceutical composition and method for treating neurodegenerative disorders |
| 02/23/2006 | WO2006020768A2 Chemically modified oligonucleotides |
| 02/23/2006 | WO2006020767A2 Thiazole based inhibitors of atp-utilizing enzymes |
| 02/23/2006 | WO2006020755A2 Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics |
| 02/23/2006 | WO2006020739A2 Compositions and methods for nutrition supplementation |
| 02/23/2006 | WO2006020727A2 Methods for treating cns disorders by administration of agents to the nasal cavity |
| 02/23/2006 | WO2006020689A1 Pharmaceutical formulation comprising an antibiotic, a triazole and a corticosteroid |
| 02/23/2006 | WO2006020684A2 Methods of regulating differentiation and treating of multiple myeloma |
| 02/23/2006 | WO2006020681A2 Compounds and methods for the treatment of ubiquitin conjugating disorders |
| 02/23/2006 | WO2006020680A2 Heterocyclic compounds as pharmaceutical agents |
| 02/23/2006 | WO2006020664A2 Ammonolysis process for the preparation of intermediates for dpp iv inhibitors |
| 02/23/2006 | WO2006020652A2 Orally administered small peptides synergize statin activity |
| 02/23/2006 | WO2006020618A1 Compositions and methods for treating leukemia |
| 02/23/2006 | WO2006020598A2 Amido compounds and their use as pharmaceuticals |
| 02/23/2006 | WO2006020573A2 Noncardiotoxic pharmaceutical compounds |
| 02/23/2006 | WO2006020561A2 Antibacterial agents |
| 02/23/2006 | WO2006020534A2 Stabilized desloratadine composition |
| 02/23/2006 | WO2006020417A2 Alkene mimics |
| 02/23/2006 | WO2006020403A2 3-halo-2-oxopropionate salts and esters as novel anticancer agents |
| 02/23/2006 | WO2006020358A2 Novel biphenyl compounds and their use |
| 02/23/2006 | WO2006020291A2 Vitamin b12 compositions |
| 02/23/2006 | WO2006020277A2 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 02/23/2006 | WO2006020276A2 Antiviral compounds |
| 02/23/2006 | WO2006020244A2 Compositions and methods related to heart failure |
| 02/23/2006 | WO2006020179A2 Oligomeric ketone compounds |
| 02/23/2006 | WO2006020156A2 Heterocyclic dye compounds for in vivo imaging and diagnosis of alzheimer’s disease |
| 02/23/2006 | WO2006020137A2 Oligomeric compounds |
| 02/23/2006 | WO2006020127A1 Medical device for delivering biologically active material |
| 02/23/2006 | WO2006020082A1 Inhibitors of hcv replication |
| 02/23/2006 | WO2006020070A2 Indanylamino uracils and their use as antioxidants and neuroprotectants |
| 02/23/2006 | WO2006020049A2 Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| 02/23/2006 | WO2006020027A1 Composition and method for treating hyperproliferative diseases |
| 02/23/2006 | WO2006020017A2 Dipeptidyl peptidase inhibitors |
| 02/23/2006 | WO2006020004A2 Histone deacetylase inhibitors |
| 02/23/2006 | WO2006020003A2 Ophthalmic compositions for treating ocular hypertension |
| 02/23/2006 | WO2006019978A2 Compositions and methods for diagnosis and treatment of epilepsy |
| 02/23/2006 | WO2006019965A2 Dipeptidyl peptidase inhibitors |
| 02/23/2006 | WO2006019955A2 Antiviral methods and compositions |
| 02/23/2006 | WO2006019940A2 Pyrrolo(oxo)quinolines as 5ht ligands |
| 02/23/2006 | WO2006019926A2 Inhibition of biofilm formation |
| 02/23/2006 | WO2006019894A2 Nebulized pharmaceutical compositions for the treatment of bronchial disorders |
| 02/23/2006 | WO2006019886A2 Pyrrolo(oxo)isoquinolines as 5ht ligands |
| 02/23/2006 | WO2006019881A2 Compositions and methods for controlling biofilms and bacterial infections |
| 02/23/2006 | WO2006019855A1 Compositions capable of inhibiting reactive oxygen and carbonyl species |
| 02/23/2006 | WO2006019843A1 Methods and compositions for the administration of calcium chelators, bisphosphonates and/or citrate compounds and their pharmaceutical uses |
| 02/23/2006 | WO2006019832A1 Thienopyridines for treating hepatitis c |
| 02/23/2006 | WO2006019831A1 Methods for treating hepatitis c |
| 02/23/2006 | WO2006019824A2 Methods of treating diabetes |
| 02/23/2006 | WO2006019787A2 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 02/23/2006 | WO2006019685A2 Compounds and their preparation for the treatment of alzheimer's disease by inhibiting beta-amyloid peptide production |
| 02/23/2006 | WO2006019673A2 Jiadifenin analogs and uses thereof |
| 02/23/2006 | WO2006019660A2 (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane |
| 02/23/2006 | WO2006019659A1 Use of vitamin ds to treat kidney disease |
| 02/23/2006 | WO2006019591A1 Use of vitamin d receptor activators or vitamin d analogs to treat cardiovascular disease |
| 02/23/2006 | WO2006019497A2 Sleep-inducing compounds and methods related thereto |
| 02/23/2006 | WO2006019183A1 Mucosal immunity and mucosal vaccine and protective inoculation system using the sensitizer |
| 02/23/2006 | WO2006019169A1 3-epivitamin d3 derivative and therapeutic agent containing the same |
| 02/23/2006 | WO2006019140A1 Jelly composition |
| 02/23/2006 | WO2006019114A1 Skin-lightening agent containing polyphenol compound |
| 02/23/2006 | WO2006019037A1 Method of judging liver fibrosis stage |
| 02/23/2006 | WO2006018997A1 External preparation |
| 02/23/2006 | WO2006018861A1 An elaborate food, assimilable by coeliac persons |
| 02/23/2006 | WO2006018855A1 Novel antidiabetic compounds |
| 02/23/2006 | WO2006018850A2 Compositions for treating amyloid associated diseases |
| 02/23/2006 | WO2006018846A2 Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4h- carbazol-4-one and ondansetron therefrom |
| 02/23/2006 | WO2006018815A1 Piperazine derivatives as adrenergic receptor antagonists |
| 02/23/2006 | WO2006018807A1 Crystalline forms of cefdinir |
| 02/23/2006 | WO2006018732A1 Androgen modulators |
| 02/23/2006 | WO2006018727A2 Triazolopyridine compounds useful for the treatment of inflammation |
| 02/23/2006 | WO2006018723A2 Androgen modulators |
| 02/23/2006 | WO2006018718A2 Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors |
| 02/23/2006 | WO2006018708A2 Pyrrolidine derivatives as muscarinic receptor antagonists |
| 02/23/2006 | WO2006018682A2 Oxazolidinone derivatives as antimicrobials |
| 02/23/2006 | WO2006018657A1 Hdac inhibitors and methods of use thereof |
| 02/23/2006 | WO2006018655A1 Use of xenon as neuroprotectant in a neonatal subject |
| 02/23/2006 | WO2006018649A1 Arene ruthenium (ii) compounds and their use in cancer therapy |
| 02/23/2006 | WO2006018633A1 Use of gsk-3 inhibitors for the treatment of prostate cancer |
| 02/23/2006 | WO2006018625A2 Peripheral benzodiazepine receptor independent superoxide generation |
| 02/23/2006 | WO2006018609A2 Anti-inflammatory agents |
| 02/23/2006 | WO2006018544A1 Composition containing a thiophenic or benzothiophenic compound and exhibiting a pump nora inhibiting activity |
| 02/23/2006 | WO2006018538A1 Medicament for the treatment of central nervous system disorders |
| 02/23/2006 | WO2006018521A2 Compounds and methods for controlling alcohol intake |
| 02/23/2006 | WO2006018501A1 Galenic applications of self-emulsifying mixtures of lipidic excipients |
| 02/23/2006 | WO2006018392A1 Aerosol formulation for inhalation, containing an anticholinergenic agent |
| 02/23/2006 | WO2006018326A1 Novel biaromatic compounds that activate ppar type receptors, and use thereof in cosmetic or pharmaceutical compositions |
| 02/23/2006 | WO2006018325A1 Novel biaromatic compounds which activate receptors of ppar type and their use in cosmetic or pharmaceutical compositions |
| 02/23/2006 | WO2006018318A1 Liquid paroxetine compositions |
| 02/23/2006 | WO2006018308A1 5-ht7 receptor antagonists |
| 02/23/2006 | WO2006018280A2 Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament |
| 02/23/2006 | WO2006018279A2 Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament |
| 02/23/2006 | WO2006018188A2 Substituted hydantoins |